Due: October 8, 2025
The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) focused on surveying current industry capabilities in the engineering, testing, and manufacturing of solutions capable of neutralizing a broad spectrum of acetylcholinesterase (AChE) inhibitors before they affect nervous system targets. The information gathered by this RFI will be shared with relevant interested Government parties to help inform future development and procurement efforts. This is not a solicitation and JPEO-CBRND is not requesting proposals at this time.
This effort seeks to identify medical technologies and solutions that can be leveraged to provide prophylactic[1] protection against AChE inhibitor exposure to the U. S. Warfighter. The objective is to enable military personnel to maintain functionality in an AChE inhibitor contaminated environment and/or to allow for rapid recovery and return to duty following exposure. The Department of Defense (DoD) is seeking innovative solutions from all potential medical technology or solution providers in support of two Fiscal Year 2027 (FY27) new start programs: Beacon and Prophylactic Technology System (ProTecS).